Chronic toxicity and long‑term outcome in intraoperative electron radiotherapy as boost followed by whole‑breast irradiation

• G. Oses ^[1] ; C. Cases ^[1] ; I. Valduvieco ^[1] ; B. Farrús ^[1] ; I. Alonso ^[1] ; X. Caparrós ^[1] ; J. Mases ^[1] ; D. Muñoz Guglielmetti ^[1] ; A. Biete ^[1] ; C. Castro ^[1] ; E. Escudero ^[1] ; M. Molina ^[1] ; A. Herreros ^[1] ; J. Saez ^[1] ; M. Mollà ^[1]
  1. [1] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 8, 2021, págs. 1593-1600
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose The administration of a dose boost to the tumor bed after breast-conserving surgery has proven to reduce local recurrence. Intra-operative electron radiotherapy (IOERT) ofers an alternative method to deliver a boost with several advantages, such as direct visualization of the tumor bed, less inter- and intrafraction motion and a reduction in the number of medical appointments. The objective of our study is to assess chronic toxicity and long-term outcome for our patients after IOERT boost.

    Material and methods Forty-six patients treated at our institution between July 2013 and June 2020 with IOERT boost during Breast-Conserving Surgery and consecutive whole breast irradiation were prospectively analyzed. A 10–12 Gy boost was prescribed to 42 patients and 4 patients received a 20 Gy boost. An analysis for overall survival, local relapse and distant progression was performed. Acute and chronic toxicity was assessed by CTCAE 4.0.

    Results The median age was 64.5 years (40–90). The median follow-up was 62 months (4–86). We had no local recurrences but 2 patients (4.3%) presented a distant recurrence. Mean pathological tumor size was 16 mm (6–52). 84.8% (39) of the patients had invasive ductal carcinoma. 52.2% (24) presented histological grade II. 52.2% (24) were Luminal A like, 21.7% (10) Luminal B like, 13% (6) HER2 positive, 13% (6) triple negative. No Grade 3–4 chronic toxicity was observed. Grade 1–2 fbrosis was evidenced in 13% (6) of the patients, 4.3% (2) patients presented fat necrosis, 6.5% (3) presented seroma, 4.3% (2) had localized pain, 2.2% (1) presented localized hematoma and 2.2% (1) presented localized edema.

    Conclusions IOERT boost in breast cancer treatment during BCS is a safe option with low chronic toxicity. The recurrence rates are comparable to published data and emphasize that IOERT as boost is an efective treatment